BioCryst Pharmaceuticals, Inc. (BCRX) Holdings Held by California Public Employees Retirement System

California Public Employees Retirement System held its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 118,300 shares of the biotechnology company’s stock at the close of the 2nd quarter. California Public Employees Retirement System owned about 0.15% of BioCryst Pharmaceuticals worth $658,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in BCRX. FMR LLC boosted its position in BioCryst Pharmaceuticals by 114.5% during the 2nd quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock worth $17,373,000 after acquiring an additional 1,667,791 shares during the period. Vanguard Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 49.1% during the 1st quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after purchasing an additional 1,651,292 shares in the last quarter. Artal Group S.A. raised its stake in shares of BioCryst Pharmaceuticals by 70.0% during the 2nd quarter. Artal Group S.A. now owns 850,000 shares of the biotechnology company’s stock worth $4,726,000 after purchasing an additional 350,000 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 49.5% during the 1st quarter. Geode Capital Management LLC now owns 773,115 shares of the biotechnology company’s stock worth $6,493,000 after purchasing an additional 255,975 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of BioCryst Pharmaceuticals by 12.8% during the 2nd quarter. Jennison Associates LLC now owns 2,080,818 shares of the biotechnology company’s stock worth $11,569,000 after purchasing an additional 236,182 shares in the last quarter. Hedge funds and other institutional investors own 71.30% of the company’s stock.

BioCryst Pharmaceuticals, Inc. (BCRX) opened at $4.52 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53. BioCryst Pharmaceuticals, Inc. has a 1 year low of $3.95 and a 1 year high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The company had revenue of $8.76 million for the quarter, compared to analyst estimates of $5.05 million. During the same quarter last year, the firm earned ($0.16) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 12.9% compared to the same quarter last year. equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.72 EPS for the current year.

In related news, Director Fred E. Cohen sold 54,250 shares of the business’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the sale, the director now owns 173,660 shares of the company’s stock, valued at approximately $941,237.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO William P. Sheridan sold 64,310 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/19/biocryst-pharmaceuticals-inc-bcrx-holdings-held-by-california-public-employees-retirement-system.html.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Jefferies Group LLC raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the stock from $5.00 to $7.00 in a research note on Wednesday, September 6th. HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. J P Morgan Chase & Co raised BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $6.00 to $9.00 in a research note on Tuesday, September 5th. Finally, Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $9.13.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply